Tangshen 1 Number Decoction in Treating Early Diabetic Nephropathy with 44 Cases

GUO Cun-xia; CHEN Xiao-yong; XIE Hong-xia; CHEN Hui; ZHANG Jian-wei

doi:10.13422/j.cnki.syfjx.2014140211

您当前的位置：

首页 >

文章列表页 >

Tangshen 1 Number Decoction in Treating Early Diabetic Nephropathy with 44 Cases

更新时间：2024-01-04

- Tangshen 1 Number Decoction in Treating Early Diabetic Nephropathy with 44 Cases
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 14, Pages: 211-214(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014140211
  CLC： R259;R277.5
- Published：2014
- 稿件说明：
移动端阅览
GUO Cun-xia, CHEN Xiao-yong, XIE Hong-xia, et al. Tangshen 1 Number Decoction in Treating Early Diabetic Nephropathy with 44 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(14): 211-214.
DOI：

GUO Cun-xia, CHEN Xiao-yong, XIE Hong-xia, et al. Tangshen 1 Number Decoction in Treating Early Diabetic Nephropathy with 44 Cases[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(14): 211-214. DOI： 10.13422/j.cnki.syfjx.2014140211.

摘要

目的：观察糖肾1号方治疗早期糖尿病肾病的临床疗效及对人组织型纤溶酶原激活剂（t-PA）和纤溶酶原激活剂抑制因子（PAI-1）的影响。方法： 88例患者采用随机按数字法分为观察组和对照组各44例。在控制血压和血糖的基础上，对照组服用卡托普利片，12.5 mg/次，3次/d；观察组在对照组治疗的基础上加用糖肾1号方，1剂/d。两组疗程均为12周。检测治疗前后24 h尿蛋白（UAER），尿微量白蛋白与肌酐的比值（ACR）、空腹血糖（FPG）、和糖化血红蛋白（HbAlc）；检测治疗前后胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）水平；检测治疗前后血清t-PA和PAI-1水平，检测治疗前后血浆D-二聚体（D-D）、血小板聚集率和血浆纤维蛋白原（FIB）。结果：观察组总有效率90.91%，对照组为68.18%，观察组优于对照组（P<0.05）；治疗后观察组UAER和ACR水平低于对照组（P<0.01）；治疗后观察组TC，TG，LDL-C水平低于对照组（P<0.01），HDL-C水平高于对照组（P<0.01）；观察组t-PA升高，并高于对照组（P<0.01），观察组PAI-1水平下降，并低于对照组（P<0.01）；治疗后观察组FIB，D-D和血小板聚集率均比治疗前下降，并低于对照组（P<0.01）。结论：糖肾1号方能调节t-PA/PAI-1活性，降低D-D，FIB和血小板聚集率，改善脂代谢，降低血液黏度，减少UAER，对早期DN肾功能有一定保护作用。

Abstract

Objective: Observe clinical effect of Tangshen 1 number decoction and influence to People tissue type plasminogen activat(t-PA) and plasminogen activator inhibitor(PAI-1) in treating early diabetic nephropathy. Method: Eighty-eight patients were randomly divided into control group (44 cases) and observation group (44 cases)by random number table.On the basis treatment of controlling blood pressure and blood glucose

patients in control group received captopril

12.5 mg/time

3 times/day.Based on the treatment of control group

patients in observation group received Tangshen 1 number decoction

1 dose/day.Course of treatment in two groups were both 12 weeks.Before and after treatment

24 hours urinary albumin excretion rate(UAER)

the ratio of microalbuminuria and creatinine

fasting plasma glucose(FPG) and hemoglobin Alc were detected.Levels of total cholesterol(TC)

triglyceride(TG)

high-density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were detected.Levels of serous t-PA and PAI-1 were also detected.And D-dimer(D-D) in plasma

platelet aggregation and plasma fibrinogen(FIB) were detected. Result: The total effective rate of curative effect in observation group was 90.91% superior to 68.18% in control group(P<0.05).After treatment

levels of UAER and ACR in observation group were lower than those in control group(P<0.01).And levels of TC

TG and LDL-C in observation group were lower than those in control group(P<0.01)

but level of HDL-C in observation group was higher than in control group(P<0.01).Ievel of t-PA in observation group increased

and which was higher than in control group(P<0.01).Ievel of PAI-1 in observation group decreased

and which was lower than in control group(P<0.01).Ievel of FIB

D-D and platelet aggregation in observation group decreased

and which were lower than those in control group(P<0.01). Conclusion: Tangshen 1 number decoction can regulate the activity of t-PA or PAI-1 and reduce levels of D-D

FIB and platelet aggregation

it can also ameliorate lipid metabolism

reduce blood viscosity and UAER

there was a protection for renal function of early diabetic nephropathy.

关键词

Keywords

references

Views

109

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Modified Buyang Huanwu Tang Combined with Sanrentang in Treatment of Spleen and Kidney Deficiency and Damp-heat and Blood Stasis Syndrome in Early Diabetic Nephropathy

Curative Effect Observation on Mongolian SA Dew de Di+Xieri GA-4 Soup for Early Diabetic Nnephropathy

Impact of Tangshenning to Level of HGF,CysC and TGF- in Patients with Two Deficiency of Qi and Yin and Blood Stasis Type of Early Diabetic Nephropathy

Protection Study of Tangshenbao Granules Combined with Enalapril Maleate Tablets in Treating Patients with Early Diabetic Nephropathy

Related Author

Guo-dong HUANG

Lin-kun CAI

Jia-li GAN

Han-yu XUE

Qiong-he HUANG

Ya-lan HUANG

WAGN Yu-jin

MA Ju-li

Related Institution

Guangxi University of Chinese Medicine

International Zhuang Medical Hospital Affiliated to Guangxi University of Chinese Medicine

Shaanxi University of Chinsse Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰